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Sixteen percent (n = 3,025) of the caregivers had a child with an ASD diagnosis. 
As compared to caregivers of children with MHC only, caregivers of children with 
ASD were significantly more likely to report issues with availability (AOR = 2.16, 
95% CI = 1.66-2.82), information (AOR = 1.89, 95% CI = 1.46-2.45), eligibility (AOR = 
1.80, 95% CI = 1.38-2.37), cost (AOR = 1.67, 95% CI = 1.31-2.14), and appointments 
(AOR = 1.35, 95% CI = 1.09-1.68). When compared to the DD & MHC group, the 
ASD group was found to be significantly more likely to report issues with 
availability, obtaining information, and cost of services. CONCLUSIONS: ASD 
caregivers reported greater difficulty with all five service difficulty measures as 
compared to caregivers of children with MHC only. However, ASD group reported 
greater problems only in availability, obtaining information, and cost of services, 
when compared to DD & MHC group.  
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OBJECTIVES: To use administrative claims to examine geographic variation 
trends in ADD diagnostic prevalence, medication use and associated medical and 
pharmacy costs. METHODS: A retrospective design and descriptive analysis of 
continuously enrolled (medical and pharmacy benefits) commercial members 
aged four to 40 between January 1, 2008 and December 31, 2010 from 
MarketScan®Commercial Claims and Encounters dataset. Key metrics included 
percent of continuously enrolled patients with ADD diagnosis, patients with ADD 
medication use and associated pharmacy and medical costs per enrollee. ADD 
diagnosis was defined as having a medical diagnostic code (ICD9) of 3140 at any 
time during a given year. Medication use was defined as having at least one 
claim for amphetamines, attention-deficit/hyperactivity-disorder agents or 
stimulants. RESULTS: The datasets comprised of 11.8, 12 and 13 million enrollees 
in 2008, 2009 and 2010, respectively. Results indicate that although the diagnostic 
prevalence, medication use and associated medical and pharmacy costs were 
the highest in the South throughout the study period, Northeast region had the 
highest growth rate. Increasing by 34.1% from 1.9% to 2.5% for patients 
diagnosed and by 43.0% from 2.4% to 3.5% for patients treated with ADD 
medications. Growing at rate of 59.0% from $34.21 in 2008 to $54.39 in 2010, 
Northeast outpaced the other regions by more than 24.1% on ADD related 
medical and pharmacy spend per enrollee. CONCLUSIONS: Northeast is the 
fastest growing region for ADD diagnosis, medication use and related spend. 
Further research is warranted to examine the factors underlying this trend. The 
findings suggest consideration of utilization management programs and cost 
containment strategies to ensure appropriate access, patient safety and cost-
effective use of ADD medications.  
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OBJECTIVES: Bipolar disorder is a costly severe mental illness with high rates of 
hospitalizations compared to several other behavioral disorders. This study aims 
to compare all-cause and mental health-related hospitalizations among adult 
patients with bipolar disorder 6-months before and after initiating lurasidone, an 
atypical antipsychotic agent. METHODS: A retrospective analysis of health 
insurance claims from the Truven Health MarketScan Commercial Database was 
conducted. The study population included individuals ages 18–64, who initiated 
lurasidone between October 1, 2010 to September 30, 2011 (initiation date=index), 
had ≥ 1 inpatient or ≥ 2 outpatient medical claims with an ICD-9-CM diagnosis 
code for bipolar disorder and had continuous health benefit coverage during the 
study period. All-cause hospitalizations and mental health-related 
hospitalizations associated with a primary diagnosis code for a mental health 
disorder were evaluated for the 6-months pre- and post-index date. Proportions 
of patients with hospitalizations and mean number of hospitalizations were 
compared using chi-square and paired t-test, respectively. RESULTS: The study 
population (N=234) was predominantly female (68.8%) with a mean age of 41.6 
years. Common pre-index comorbidities included depression (61.5%), anxiety 
(24.4%), hypertension (20.5%) and diabetes (20.1%). The proportion of patients 
with all-cause hospitalizations decreased from 33.3% in the pre-period to 21.4% 
in the post-period (p = 0.0005). Similarly, the proportion of patients with mental 
health-related hospitalizations decreased from 27.8% to 17.1% between the pre-
and post-index periods (p=0.0006). The mean numbers of hospitalizations in the 
pre- and post-index periods were 0.6 and 0.3 for all-cause (p=0.0175) and 0.5 and 
0.2 for mental health-related conditions (p=0.0310). CONCLUSIONS: In this 
analysis of patients with bipolar disorder, significantly smaller proportions of 
patients were hospitalized for all-cause and mental health-related diagnoses in 
the 6 months after initiating lurasidone compared to the 6 months before 
initiation. The mean numbers of hospitalizations were also significantly lower in 
the 6-months after initiation on lurasidone.  
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OBJECTIVES: To investigate the use of health care utilizations and direct medical 
costs for patients with depression. METHODS: This study combined major 
clinical information of 1183 depressed patients who registered for the 
prospective depressed patients cohort study (CRESCEND: the Clinical Research 
Center for Depression Study) from January 2006 to August 2008 and the health 
insurance claims filed with the Health Insurance Review & Assessment Service, 
HIRA. Of these patients, 834 who had HAMD-17 scores > 14 at screen visit and 
more than one time claim for reimbursement of antidepressants at HIRA after 
their cohort enrollment were subject to this analysis on their use of health care 
institutions, in-patient and out-patient, as well as their medical costs. RESULTS: 
The hospital visit by out-patients with depression was 17.3 times a year with the 
average hospitalization rate at 20.9%. The times of hospital visits tended to 
increase in cases of elderly patients, patients with comorbidities, patients 
treated with combination therapy, patients prescribed with NADs and patients 
treated with multiple drugs in combination. The hospitalization rate tended to 
increase in cases of patients with comorbidities, severer patients in HAMD 
scores, patients treated with combination therapy, Patients prescribed with 
NADs and patients treated with multiple drugs in combination. In direct medical 
costs, drug expenses represented 60.6%. The costs tended to increase in elderly 
patients, patients with comorbidities, severer patients in HAMD scores, 
combination therapy patients, patients prescribed with NADs than SSRI and 
patients prescribed with multiple drugs. Drug expenses increased with the rise 
in out-patient visits, and medical costs at 12 months increased in out-patients 
with less hospital visits. CONCLUSIONS: SSRIs are first-line treatment to save 
direct medical costs. HAMD is regarded as the most relevant measure not only 
for the severity of depression but also for the estimation of the use of health care 
institutions and medical costs.  
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OBJECTIVES: Buprenorphine/naloxone combination (BUP/NAL) is recommended 
in the treatment of opioid dependence. Clinical guidelines do not specify the 
minimum duration of treatment required to achieve long-term remission. This 
study evaluated the impact of treatment persistence on health care charges. 
METHODS: Study was conducted on a US insurance claims database. It included 
patients initiating treatment with BUP/NAL claim between November 2006 and 
December 2011, not previously treated with buprenorphine, with at least one 
repeat claim after 30 days. Discontinuation was defined as absence of BUP/NAL 
claim for 90 days. Health care charges over 12 months were compared between 
persistent and non-persistent patients, adjusting on baseline characteristics 
(demographics, comorbidities, treatment, and resource utilization before index 
date). RESULTS: Of 19,008 patients with an incident claim of BUP/NAL, 35.7% 
appeared to be short-term users and were excluded. Among the remaining 
12,231 patients, the average duration of follow-up was 12.9 months, and 2846 
were followed for at least two years. The probability of continuing treatment 
over 24 months was 40.9%. Patients under 25 years old, with a diagnosis of 
hepatitis or soft tissue infection were more likely to discontinue. Patients treated 
for at least 12 months had lower mean total charges compared to non-persistent 
patients ($22,912 vs. $31,687; p<0.0001), adjusting on baseline characteristics. 
Among non-persistent patients, total charges per quarter reached a maximum 
during the first trimester following discontinuation (+91% compared to period 
from 6 to 4 months before discontinuation, p<0.0001), and were also significantly 
higher in the second trimester after discontinuation (+52%, p=0.0003), compared 
with before discontinuation. Main drivers of excess charges were hospitalization 
and outpatient visits. Majority of long-term users of BUP/NAL discontinued 
treatment before 24 months. CONCLUSIONS: Non-persistence was associated 
with higher charges and evidence was consistent with a causal relationship 
between discontinuation and increased charges. Treatment persistence 
improvement may lead to cost savings.  
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OBJECTIVES: To evaluate if the Iowa Medicaid duloxetine depression Prior 
Authorization (PA) policy, implemented may 24, 2010, inadvertently increased 
atypical antipsychotic use in depressed patients. We compare initiations of 
duloxetine and other relevant medications for depression in Iowa before  
and after PA implementation and in Missouri, which had no duloxetine  
PA. METHODS: Using de-identified Iowa and Missouri Medicaid claims data 
(1999-2010), two cohorts were selected from each state: 2010 policy change 
cohort (index date: 5/24/2010) and 2009 control cohort (index date: 5/24/2009). 
Patients had to have ≥1 inpatient or 2 other medical claims with a depression 
diagnosis pre-index; ≥1 antidepressant or antipsychotic claim during the  
